PIECAPITAL

The VC division covers pre-seed through Series B rounds, while the private equity practice concentrates on mid-market growth and succession-stage companies. This dual-stage approach means the firm can back a company at its technical inception and remain engaged through commercial maturity. The later-stage PE vehicle also provides a path for portfolio companies that outgrow the venture mandate.

The firm focuses on enterprise software, precision biology, climate adaptation technologies, diagnostics platforms, industrial automation, and renewable-component supply chains. The common thread is technical differentiation requiring subject-matter expertise to evaluate. PIECAPITAL does not publicly disclose sector exclusions, but its deal history shows no exposure to consumer internet, generalist fintech lending, or speculative digital assets.

PIECAPITAL operates two distinct strategies under one roof: an early-stage venture capital fund and a mid-market private equity fund. This is a deliberate structural choice, not a fund-of-funds wrapper. Each strategy has its own investment committee process, though the firm draws shared operational and research resources across both.

The firm leans on research institution partnerships, technology grant co-investment networks, and Dutch institutional LP relationships. The Amsterdam headquarters positions the team to access the Benelux innovation corridor, with active sourcing across the DACH and Nordic regions. PIECAPITAL's model favors proprietary introductions and academic spin-out networks over broad auction participation.

PIECAPITAL participates in syndicated rounds when complementary capital or specialized expertise is needed, and it executes direct proprietary transactions particularly on the private equity side. The firm has not publicly restricted co-investment rights, and its dual-horizon structure often makes it a natural partner for later-stage funds seeking a knowledgeable early-stage entry point.